J
Julian C. van Capelleveen
Researcher at University of Amsterdam
Publications - 21
Citations - 1541
Julian C. van Capelleveen is an academic researcher from University of Amsterdam. The author has contributed to research in topics: Cholesterol & Coronary artery disease. The author has an hindex of 11, co-authored 21 publications receiving 1219 citations.
Papers
More filters
Journal ArticleDOI
Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials
Nicholas J. Viney,Julian C. van Capelleveen,Richard S. Geary,Shuting Xia,Joseph A. Tami,Rosie Z. Yu,Santica M. Marcovina,Steven G. Hughes,Mark J. Graham,Rosanne M. Crooke,Stanley T. Crooke,Joseph L. Witztum,Erik S.G. Stroes,Sotirios Tsimikas,Sotirios Tsimikas +14 more
TL;DR: A phase 1/2a first-in-man trial and a phase 2 trial aimed to assess the efficacy, safety, and tolerability of two unique antisense oligonucleotides designed to lower Lp(a) concentrations.
Journal ArticleDOI
Coding Variation in ANGPTL4, LPL, and SVEP1 and the Risk of Coronary Disease
Nathan O. Stitziel,Kathleen Stirrups,Nicholas G. D. Masca,Jeanette Erdmann,Paola G. Ferrario,Inke R. Koenig,Peter Weeke,Tom R. Webb,Paul L. Auer,Ursula M. Schick,Yingchang Lu,He Zhang,Marie-Pierre Dubé,Anuj Goel,Martin Farrall,Gina M. Peloso,Hong-Hee Won,Ron Do,Erik P A Van Iperen,Stavroula Kanoni,Jochen Kruppa,Anubha Mahajan,Robert A. Scott,Christina Willenborg,Peter S. Braund,Julian C. van Capelleveen,Alex S. F. Doney,Louise A. Donnelly,Rosanna Asselta,Piera Angelica Merlini,Stefano Duga,Nicola Marziliano,Josh C. Denny,Christian M. Shaffer,Nour Eddine El-Mokhtari,Andre Franke,Omri Gottesman,Stefanie Heilmann,Christian Hengstenberg,Per Hoffmann,Oddgeir L. Holmen,Kristian Hveem,Jan-Håkan Jansson,Karl-Heinz Joeckel,Thorsten Kessler,Jennifer Kriebel,Karl L. Laugwitz,Eirini Marouli,Nicola Martinelli,Mark I. McCarthy,Natalie R. van Zuydam,Christa Meisinger,Tõnu Esko,Evelin Mihailov,Stefan A. Escher,Maris Alver,Susanne Moebus,Andrew D. Morris,Martina Mueller-Nurasyid,Majid Nikpay,Oliviero Olivieri,Louis-Philippe Lemieux Perreault,Alaa AlQarawi,Neil R. Robertson,Karen O. Akinsanya,Dermot F. Reilly,Thomas F. Vogt,Wu Yin,Folkert W. Asselbergs,Charles Kooperberg,Rebecca D. Jackson,Eli A. Stahl,Konstantin Strauch,Tibor V. Varga,Melanie Waldenberger,Lingyao Zeng,Aldi T. Kraja,Chunyu Liu,Georg Ehret,Christopher Newton-Cheh,Daniel I. Chasman,Rajiv Chowdhury,Marco M Ferrario,Ian Ford,J. Wouter Jukema,Frank Kee,Kari Kuulasmaa,Børge G. Nordestgaard,Markus Perola,Danish Saleheen,Naveed Sattar,Praveen Surendran,David-Alexandre Trégouët,Robin Young,Joanna M. M. Howson,Adam S. Butterworth,John Danesh,Diego Ardissino,Erwin P. Bottinger,Raimund Erbel,Paul W. Franks,Domenico Girelli,Alistair S. Hall,G. Kees Hovingh,Adnan Kastrati,Wolfgang Lieb,Thomas Meitinger,William E. Kraus,Svati H. Shah,Ruth McPherson,Marju Orho-Melander,Olle Melander,Andres Metspalu,Colin N. A. Palmer,Annette Peters,Daniel J. Rader,Muredach P. Reilly,Ruth J. F. Loos,Alexander P. Reiner,Dan M. Roden,Jean-Claude Tardif,John R. Thompson,Nicholas J. Wareham,Hugh Watkins,Cristen J. Willer,Sekar Kathiresan,Panos Deloukas,Nilesh J. Samani,Heribert Schunkert +128 more
TL;DR: It was found that carriers of loss-of-function mutations in ANGPTL4 had triglyceride levels that were lower than those among noncarriers; these mutations were also associated with protection from coronary artery disease.
Journal ArticleDOI
Systematic Evaluation of Pleiotropy Identifies 6 Further Loci Associated With Coronary Artery Disease
Tom R. Webb,Jeanette Erdmann,Kathleen Stirrups,Nathan O. Stitziel,Nicholas G. D. Masca,Henning Jansen,Stavroula Kanoni,Christopher P. Nelson,Paola G. Ferrario,Inke R. König,John D. Eicher,Andrew D. Johnson,Stephen E. Hamby,Christer Betsholtz,Arno Ruusalepp,Oscar Franzén,Eric E. Schadt,Johan Björkegren,Peter Weeke,Paul L. Auer,Ursula M. Schick,Ursula M. Schick,Yingchang Lu,He Zhang,Marie-Pierre Dubé,Anuj Goel,Martin Farrall,Gina M. Peloso,Hong-Hee Won,Ron Do,Erik P A Van Iperen,Jochen Kruppa,Anubha Mahajan,Robert A. Scott,Christina Willenborg,Peter S. Braund,Julian C. van Capelleveen,Alex S. F. Doney,Louise A. Donnelly,Rosanna Asselta,Pier Angelica Merlini,Stefano Duga,Nicola Marziliano,Josh C. Denny,Christian M. Shaffer,Nour Eddine El-Mokhtari,Andre Franke,Stefanie Heilmann,Christian Hengstenberg,Per Hoffmann,Oddgeir L. Holmen,Kristian Hveem,Jan-Håkan Jansson,Karl-Heinz Jöckel,Thorsten Kessler,Jennifer Kriebel,Karl L. Laugwitz,Eirini Marouli,Nicola Martinelli,Mark I. McCarthy,Natalie R. van Zuydam,Christa Meisinger,Tõnu Esko,Tõnu Esko,Tõnu Esko,Evelin Mihailov,Stefan A. Escher,Maris Alver,Susanne Moebus,Andrew D. Morris,Jarma Virtamo,Majid Nikpay,Oliviero Olivieri,Sylvie Provost,Alaa AlQarawi,Neil R. Robertson,Karen O. Akinsansya,Dermot F. Reilly,Thomas F. Vogt,Wu Yin,Folkert W. Asselbergs,Folkert W. Asselbergs,Charles Kooperberg,Rebecca D. Jackson,Eli A. Stahl,Martina Müller-Nurasyid,Konstantin Strauch,Tibor V. Varga,Melanie Waldenberger,Lingyao Zeng,Rajiv Chowdhury,Veikko Salomaa,Ian Ford,J. Wouter Jukema,Philippe Amouyel,Jukka Kontto,Børge G. Nordestgaard,Jean Ferrières,Danish Saleheen,Naveed Sattar,Praveen Surendran,Aline Wagner,Robin Young,Joanna M. M. Howson,Adam S. Butterworth,John Danesh,Diego Ardissino,Erwin P. Bottinger,Raimund Erbel,Paul W. Franks,Domenico Girelli,Alistair S. Hall,G. Kees Hovingh,Adnan Kastrati,Wolfgang Lieb,Thomas Meitinger,William E. Kraus,Svati H. Shah,Ruth McPherson,Marju Orho-Melander,Olle Melander,Andres Metspalu,Colin N. A. Palmer,Annette Peters,Daniel J. Rader,Muredach P. Reilly,Ruth J. F. Loos,Alexander P. Reiner,Alexander P. Reiner,Dan M. Roden,Jean-Claude Tardif,John R. Thompson,Nicholas J. Wareham,Hugh Watkins,Cristen J. Willer,Nilesh J. Samani,Heribert Schunkert,Panos Deloukas,Sekar Kathiresan +138 more
TL;DR: Several CAD loci show substantial pleiotropy, which may help us understand the mechanisms by which these loci affect CAD risk, and identify 6 new loci associated with CAD at genome-wide significance.
Journal ArticleDOI
Current therapies for lowering lipoprotein(a)
TL;DR: The past and present therapies aiming to lower Lp(a) levels will be reviewed, demonstrating that these agents have had varying degrees of success and the next challenge will be to prove that Lp (a) lowering also leads to cardiovascular benefit in patients with elevated Lp
Journal ArticleDOI
Apolipoprotein C-III Levels and Incident Coronary Artery Disease Risk: The EPIC-Norfolk Prospective Population Study.
Julian C. van Capelleveen,Sophie J. Bernelot Moens,Xiaohong Yang,John J.P. Kastelein,Nicholas J. Wareham,Aeilko H. Zwinderman,Erick S.G. Stroes,Joseph L. Witztum,G. Kees Hovingh,Kay-Tee Khaw,S. Matthijs Boekholdt,Sotirios Tsimikas +11 more
TL;DR: In this article, the authors proposed a new method for cancer detection based on protein-protein interactions, which is based on the National Institute for Health Research (NIHR) method.